Abstract
Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Results: The symptoms of constant ear fullness and severe tinnitus abated and have not returned for 2 years. In addition, the edema of the fingers and ankles have abated along with an 11 pound weight loss. Conclusions: Menière’s disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The common denominator is that these seemingly unrelated conditions affecting many organ systems all respond markedly well to amphetamine therapy. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability.
Highlights
Menière’s disease is a chronic condition manifested by episodic attacks of vertigo, tinnitus, fluctuating hearing loss, and pressure sensation in the ears related to endolymphatic hydrops of the inner ear [1]
The patient was referred to our reproductive endocrinology, infertility practice for her Menière’s syndrome by another patient, who was aware of the increased cellular permeability syndrome, and the benefits of dextroamphetamine sulfate for various chronic treatment refractory conditions
It is unlikely that there will ever be any randomized controlled studies comparing the efficacy in elagolix vs. dextroamphetamine sulfate for controlling pelvic pain because the use of dextroamphetamine sulfate is an off-label use and no pharmaceutical company can make a profit if such an expensive study demonstrated the superiority of the amphetamine in both efficacy and lack of side effects
Summary
Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Conclusions: Menière’s disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
